An observational study in Obesity, Dental Erosion and Saliva Collection, sponsored by Bilecik Seyh Edebali Universitesi. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Bilecik Seyh Edebali Universitesi · Observational
People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues.
The purpose of this study is to evaluate changes in salivary calcium levels, salivary function, and dental hard tissues in adults who begin treatment with semaglutide or tirzepatide for obesity.
Approximately 40 participants will be enrolled before starting GLP-1 receptor agonist therapy. Oral examinations, standardized intraoral photographs, saliva samples, and body weight measurements will be obtained before treatment and again after three months. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate. Dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index.
The findings from this study may improve understanding of the effects of GLP-1 receptor agonists on oral health and help healthcare professionals identify and prevent possible dental complications during treatment.
Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, have become widely used for the treatment of obesity because of their substantial effects on body weight reduction and metabolic control. As the use of these medications continues to increase, attention has shifted toward their potential systemic and oral adverse effects. Recent clinical reports and pharmacovigilance studies have described oral complaints such as xerostomia, hyposalivation, oral discomfort, altered taste perception, and dental problems in individuals receiving GLP-1 receptor agonist therapy. However, the biological mechanisms underlying these observations remain largely unknown.
Saliva is essential for maintaining oral homeostasis. It provides lubrication, buffering capacity, antimicrobial protection, and contributes to the remineralization of dental hard tissues through its mineral content, particularly calcium and phosphate ions. Alterations in salivary secretion, pH, or mineral composition may impair the protective functions of saliva, thereby increasing the susceptibility to dental erosion, enamel demineralization, and other hard tissue alterations. Although reduced salivary flow has been described in isolated reports of semaglutide users, prospective clinical evidence evaluating changes in salivary composition during GLP-1 receptor agonist therapy is currently lacking.
Weight loss associated with GLP-1 receptor agonists may also indirectly influence oral health. Gastrointestinal adverse effects, particularly nausea and vomiting, as well as changes in dietary habits, fluid intake, and gastroesophageal reflux symptoms, may increase exposure of dental tissues to acidic conditions. Furthermore, dehydration resulting from reduced oral intake or gastrointestinal symptoms may contribute to impaired salivary function. These factors may act individually or synergistically to influence the integrity of dental hard tissues during treatment.
This prospective observational cohort study aims to evaluate changes in salivary calcium concentration, salivary flow rate, salivary pH, and dental hard tissues in adults initiating semaglutide or tirzepatide therapy for obesity. Participants will undergo standardized oral examinations, body weight measurements, intraoral photography, and unstimulated whole saliva collection before treatment initiation and after three months of therapy. Dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index, while saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate using standardized laboratory procedures.
The primary objective of this study is to determine whether treatment with GLP-1 receptor agonists is associated with changes in salivary calcium concentration during the first three months of therapy. Secondary objectives include evaluating changes in salivary pH, salivary flow rate, dental hard tissue status assessed by BEWE, body weight, and standardized photographic findings. In addition, the study will investigate the relationships between weight loss, gastrointestinal symptoms, salivary alterations, and dental hard tissue changes.
Because prospective studies evaluating the oral effects of GLP-1 receptor agonists remain limited, this study is expected to provide novel clinical evidence regarding the potential impact of these medications on salivary function and dental hard tissues. The findings may contribute to the early recognition of oral changes during obesity pharmacotherapy and support the development of preventive strategies through collaboration between endocrinologists and dental professionals.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 40 is below the median of 114 across 2,154 observational studies indexed under Obesity.
Browse Obesity studies →Bilecik Seyh Edebali Universitesi is the lead sponsor of 62 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of adults (≥18 years) with obesity (BMI ≥27 kg/m²) who are prescribed semaglutide or tirzepatide for obesity management according to routine clinical practice. Participants will be recruited before initiating GLP-1 receptor agonist therapy at the Endocrinology and Metabolism outpatient clinic and will undergo standardized oral examinations and saliva assessments at baseline and after 3 months of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with obesity who are prescribed semaglutide by an endocrinologist according to routine clinical indications. Participants will undergo baseline oral examination, standardized intraoral photography, body weight assessment, and unstimulated whole saliva collection before initiating treatment. The same evaluations will be repeated after 3 months of therapy. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate, and dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index.Changes in salivary calcium concentration, salivary pH, salivary flow rate, BEWE scores, body weight, and standardized intraoral photographs will be compared between baseline and the 3-month follow-up, as well as between the two treatment groups.
Procedure: Unstimulated Whole Saliva Collection · Procedure: Salivary Analysis · Procedure: Oral Examination and BEWE Assessment · Procedure: Standardized Intraoral Photography
Adults with obesity who are prescribed tirzepatide by an endocrinologist according to routine clinical indications. Participants will undergo baseline oral examination, standardized intraoral photography, body weight assessment, and unstimulated whole saliva collection before initiating treatment. The same evaluations will be repeated after 3 months of therapy. Saliva samples will be analyzed for calcium concentration, pH, and salivary flow rate, and dental hard tissue changes will be assessed using the Basic Erosive Wear Examination (BEWE) index.Changes in salivary calcium concentration, salivary pH, salivary flow rate, BEWE scores, body weight, and standardized intraoral photographs will be compared between baseline and the 3-month follow-up, as well as between the two treatment groups.
Procedure: Unstimulated Whole Saliva Collection · Procedure: Salivary Analysis · Procedure: Oral Examination and BEWE Assessment · Procedure: Standardized Intraoral Photography
Unstimulated whole saliva will be collected for 10 minutes at baseline and after 3 months. Participants will refrain from eating, drinking, smoking, chewing gum, and performing oral hygiene procedures for at least 2 hours before sample collection. Salivary flow rate will be calculated, and saliva samples will be processed for pH measurement and calcium analysis.
Saliva samples will be centrifuged at 3,000 × g for 10 minutes at 4°C. Salivary pH will be measured, and the supernatant will be stored at -80°C until calcium concentration analysis.
Standardized oral examinations will be performed at baseline and after 3 months. Dental hard tissue status will be evaluated using the Basic Erosive Wear Examination (BEWE) index by calibrated examiners.
Standardized intraoral photographs will be obtained at baseline and after 3 months using a predefined photographic protocol. Images will be coded and evaluated for dental hard tissue changes by blinded assessors.
This study also gives Semaglutide, Tirzepatide. No intervention listed here names it: that was found by reading the record.
Change in salivary calcium concentration
Change in salivary calcium concentration (mg/dL) measured in unstimulated whole saliva using a colorimetric biochemical assay between baseline and 3 months after initiation of semaglutide or tirzepatide therapy.
Time frame: Baseline and 3 months
Change in salivary pH
Change in unstimulated salivary pH measured using a digital pH meter between baseline and 3 months.
Time frame: Baseline and 3 months
Change in unstimulated salivary flow rate
Change in unstimulated salivary flow rate (mL/min) calculated from saliva collected over a standardized 10-minute period between baseline and 3 months.
Time frame: Baseline and 3 months
Change in dental hard tissue status
Change in dental erosive wear assessed using the Basic Erosive Wear Examination (BEWE) scoring system (score 0-18) between baseline and 3 months.
Time frame: Baseline and 3 months
Change in body mass index
Change in body mass index (kg/m²) calculated from measured body weight and height between baseline and 3 months.
Time frame: Baseline and 3 months
Change in body weight
Change in body weight (kg) measured using a calibrated digital scale between baseline and 3 months.
Time frame: Baseline and 3 months
Plan to share: Yes — De-identified individual participant data underlying the primary study results will be shared upon reasonable request. The dataset will include demographic characteristics, body weight, body mass index, treatment group, medication dose, salivary calcium concentration, salivary pH, salivary flow rate, BEWE scores, and other coded clinical variables. The study protocol, statistical analysis plan, and data dictionary will also be available. Original photographs and biological specimens will not be shared. Data access will require approval of a scientifically sound research proposal and a data-sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Baseline-3 months
Access criteria: Access will be granted only to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the principal investigator and study investigators. Approved researchers will receive de-identified individual participant data, the study protocol, statistical analysis plan, and data dictionary after signing a data-sharing agreement. Data will be transferred through secure electronic methods in accordance with institutional policies, applicable regulations, and participant confidentiality requirements.
Start is estimated for Aug 2026; primary completion for Oct 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bilecik Seyh Edebali Universitesi